Regeneron
Develops antibody and genetic medicines led by Dupixent, EYLEA HD, and Libtayo.
Something off on this page? Send us feedback.
Profile
Discovers and commercializes medicines led by Dupixent for inflammatory disease, EYLEA and EYLEA HD for retinal disease, and Libtayo for cancer. Revenue combines direct product sales with profit shares from Sanofi and Bayer collaborations.
Discovers, develops, manufactures and commercializes medicines for eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, and rare disease. Dupixent anchors inflammation; EYLEA and EYLEA HD anchor retinal care; Libtayo leads oncology. Praluent, Kevzara, Evkeeza, Lynozyfic and Otarmeni extend the commercial portfolio.
Uses human-genetics research and VelociSuite technologies to discover fully human and bispecific antibodies, with most clinical candidates originating in its own laboratories. Revenue combines direct sales and collaboration economics: Sanofi records Dupixent sales worldwide and shares profits, Bayer records EYLEA sales outside the United States, and Libtayo sales are recorded directly worldwide. Regulatory approvals, manufacturing execution and these collaboration agreements remain structural dependencies.
Company facts
Key statistics
Year to date +2.3% · Average volume (30d) 726.3K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 17, 2026 | Leerink Partners | Reiterate | Market Perform | $641 | $824 |
| Aug 14, 2026 | Bernstein | Reiterate | Market Perform | $921 | $756 |
| Aug 3, 2026 | Guggenheim | Reiterate | Buy | $1,000 | $1,030 |
| Jul 31, 2026 | RBC Capital | Reiterate | Sector Perform | $707 | $737 |
| Jul 31, 2026 | Morgan Stanley | Reiterate | Equal Weight | $730 | $758 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026Q2 FY26 | $10.16 | $14.29 | +40.6% | $3.82B | $4.29B | +12.4% | +6.17% |
| Apr 29, 2026Q1 FY26 | $8.91 | $9.47 | +6.3% | $3.48B | $3.61B | +3.6% | +3.02% |
| Jan 30, 2026Q4 FY25 | $10.74 | $11.44 | +6.5% | $3.81B | $3.88B | +1.9% | +1.83% |
| Oct 28, 2025Q3 FY25 | $9.65 | $11.83 | +22.6% | $3.59B | $3.75B | +4.5% | −0.24% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $3.03B | $3.68B | $3.75B | $3.88B | $3.61B | $4.29B | |
| Gross profit | $2.56B | $3.15B | $3.23B | $3.30B | $2.94B | $3.71B | |
| Operating income | $591.7M | $1.08B | $1.03B | $879.9M | $642.9M | $1.42B | |
| Net income | $808.7M | $1.39B | $1.46B | $844.6M | $727.2M | $1.30B | |
| Diluted EPS | $7.27 | $12.81 | $13.62 | $7.86 | $6.75 | $12.20 | |
| Gross margin | 84.7% | 85.6% | 86.1% | 84.9% | 81.4% | 86.6% | |
| Operating margin | 19.5% | 29.4% | 27.3% | 22.7% | 17.8% | 33.1% |
Fiscal years (4-quarter sums)FY21 $16.07B · FY22 $12.17B · FY23 $13.12B · FY24 $14.20B · FY25 $14.34B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $7.99B · Total debt $1.99B · Total assets $41.73B · Shareholders' equity $31.71B
Dividends
Last raised to $0.94 from $0.88 in Feb 2026. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Aug 18, 2026 | Aug 18 | Aug 31 | $0.94 | |
| May 20, 2026 | May 20 | Jun 4 | $0.94 | |
| Feb 20, 2026 | Feb 20 | Mar 5 | $0.94 | raised from $0.88 |
| Nov 20, 2025 | Nov 20 | Dec 5 | $0.88 | |
| Aug 18, 2025 | Aug 18 | Sep 3 | $0.88 | |
| May 20, 2025 | May 20 | Jun 6 | $0.88 | |
| Feb 20, 2025 | Feb 20 | Mar 20 | $0.88 |
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 103.02M · Float 100.94M · 98.0% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 9.11M | 8.85% | 13F | Aug 7, 2026 |
| Vanguard Capital Management LLC | 6.63M | 6.44% | 13F | Aug 13, 2026 |
| Dodge & Cox | 4.87M | 4.73% | 13F | Aug 13, 2026 |
| State Street Corp | 4.83M | 4.69% | 13F | Aug 7, 2026 |
| Invesco Ltd. | 3.94M | 3.83% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 10, 2026 | Kathryn Guarini | director | −400 | $800.00 |
| Aug 10, 2026 | Huda Y. Zoghbi | director | −800 | $800.00 |
| Jul 2, 2026 | Arthur F. Ryan | director | −200 | $650.15 |
| May 1, 2026 | Arthur F. Ryan | director | −100 | $705.24 |
| Apr 1, 2026 | Arthur F. Ryan | director | −100 | $777.27 |
Peers
- Sanofi (ADR)
Dupixent partner advancing rival amlitelimab in the same AD space.
- Merck
Keytruda is the PD-1 standard-of-care Libtayo must displace in CSCC and NSCLC.
- AstraZeneca (ADR)
Tezspire and Fasenra challenge Dupixent in the severe asthma market.
- Amgen
Only EYLEA biosimilar on the US market; Tezspire partner; PCSK9 adversary.
- Eli Lilly
Ebglyss (lebrikizumab) directly challenges Dupixent in atopic dermatitis.
- GSK (ADR)
Nucala competes with Dupixent in eosinophilic asthma, CRSwNP, and COPD.
- Bristol-Myers Squibb
Opdivo contests Libtayo in PD-1 NSCLC and non-melanoma skin cancers.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Regeneron | $793.21 | −0.11% | $81.82B | 19.6 | 13.1 | 5.3 | +16.7% |
| Sanofi (ADR) | $44.83 | +0.02% | $107.62B | 78.9 | — | 1.9 | +11.2% |
| Merck | $148.19 | −0.08% | $366.18B | 118.7 | 17.2 | 5.5 | +5.1% |
| AstraZeneca (ADR) | $161.79 | −0.55% | $252.33B | 24.4 | 15.2 | 4.1 | +6.4% |
| Amgen | $430.27 | −0.49% | $233.38B | 26.9 | 18.4 | 6.1 | +9.7% |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| GSK (ADR) | $50.57 | −0.51% | $101.82B | 15.8 | 9.2 | 2.2 | +2.7% |
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| Median | 26.9 | 16.2 | 4.1 | +6.4% |